Sheba Medical Center and Swiss-based CDMO Lonza Pharma recently announced a new collaborative venture to use the cutting-edge CocoonTM manufacturing platform to develop point-of-care CAR T-cell therapy. This joint project aims to streamline the in-house cell manufacturing process, thereby enabling a greater amount of critically ill oncology patients to access genetically engineered human CAR T-cells more efficiently.
64 search results for: Car-T Treatment
The Pediatric Hemato-Oncology Department at Sheba Medical Center provides compassionate and comprehensive care for children with cancer and blood disorders, such as lymphomas and leukemias. Our internationally renowned specialists treat approximately 1,200 inpatients and 4,000 outpatients every year. As a part of the state-of-the-art Edmond and Lily Safra Children’s Hospital, we are committed to designing…
Lonza, a Swiss biotech company, opens their new Israeli Collaborative Innovation Center (CIC) in the Life Science Park, in Haifa. This Research & Development center features 1,000 square meters of space. CIC employs staff of 15 scientific professionals. Managed by Dr. Frida Grynspan-Gotlieb, the CIC aims to take advantage of Israel’s frontline expertise in software and cell/molecular biology and engineering in order to enhance Lonza’s capabilities.
In February 2012, a family from Chelyabinsk, Russia faced a critical situation. Their 11-month old son, Dima, was seriously ill. Read about his touching recovery story and battle against leukemia.
global patient services
Global Patient Services at Sheba
CONTACT SHEBA MEDICAL CENTER
The information on this website is for general knowledge purposes only and does not constitute medical advice, diagnosis, or treatment in any form. It is not a substitute for professional medical advice from a qualified physician.
Additionally, you are browsing the official – and only – website of Sheba Medical Center and not an agent or affiliate website.